Fig. 2From: Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trialCEAC curve showing the probability that ciclosporin is cost-effective against a range of WTP threshold valuesBack to article page